Note: Where available, the PDF/Word icon below is provided to view the complete and fully formatted document

Previous Fragment    Next Fragment

Notice given 4 February 2004

*2527  Senator Allison: To ask the Minister representing the Minister for Health and Ageing—

(1) Why were the 1369 Pan Pharmaceutical products recalled in April 2003 destroyed.

(2) Were any of these products tested; if not, why not.

(3) Were any of these products the subject of reported adverse reactions or death; if so, can details be provided.

(4) For each recalled product: (a) what was the total quantity returned; (b) what was the total quantity destroyed; and (c) where were they destroyed.

*2528  Senator Allison: To ask the Minister representing the Minister for Health and Ageing—

(1) How many Pharmaceutical Benefits Scheme prescriptions have been filled each year since bupropion (Zyban SR) was approved by the Therapeutic Goods Administration (TGA) in 2000.

(2) What are the conditions for which bupropion is listed and approved.

(3) Can a copy of the TGA’s pre-market evaluation of bupropion be provided.

(4) For each year since 2000: (a) how many adverse reactions to bupropion in Australia have been reported to the Adverse Drug Reactions Advisory Committee (ADRAC); and (b) how many deaths in Australia have been attributed to the consumption of bupropion.

(5) How do the statistics for paragraph (4) compare with those for the United Kingdom, the United States of America and Canada.

(6) How many deaths and/or adverse reactions would normally warrant a Class 1 product recall.

(7) Did the TGA consider recalling this product; if so, what were its conclusions.

(8) To what are the adverse reactions and deaths attributed.

(9) What testing has the TGA conducted on bupropion.

(10) For each year since 1990, can details be provided of the 20 pharmaceuticals used in Australia which generate the most complaints to ADRAC of deaths and adverse reactions, together with a description of action taken by the TGA in relation to each drug.

*2529  Senator Allison: To ask the Minister representing the Minister for Health and Ageing—

(1) What information has the Australian Medical Workforce Advisory Committee collected in the past 2 years, in relation to which medical specialties, concerning: (a) unfilled positions; (b) elective surgery waiting time/clearance time; (c) consultation waiting time and patient access; (d) excessive hours of work; (e) price of service/level of co-payment; (f) practitioner/population ratio; (g) service substitution; (h) quality of service provision; (i) referring practitioner assessments; and (j) consumer and carer assessments.

(2) What strategies has the Government adopted to increase the number of pharmacists (and other specialist positions that are experiencing workforce shortages) available to public hospitals.

(3) How does the Government rate its performance in relation to its workforce strategies since it restricted supply in 1996.